179 related articles for article (PubMed ID: 15174977)
1. Therapeutic idiotype vaccines in B lymphoproliferative diseases.
Coscia M; Kwak LW
Expert Opin Biol Ther; 2004 Jun; 4(6):959-63. PubMed ID: 15174977
[TBL] [Abstract][Full Text] [Related]
2. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
4. Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma.
Hollander N
Crit Rev Immunol; 2009; 29(5):399-418. PubMed ID: 20001888
[TBL] [Abstract][Full Text] [Related]
5. The role of idiotype vaccines in the treatment of human B-cell malignancies.
Bendandi M
Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
[TBL] [Abstract][Full Text] [Related]
6. Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing.
Frøyland M; Ruffini PA; Thompson KM; Gedde-Dahl T; Fredriksen AB; Bogen B
Eur J Haematol; 2011 May; 86(5):385-95. PubMed ID: 21332794
[TBL] [Abstract][Full Text] [Related]
7. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
Hurvitz SA; Timmerman JM
Expert Opin Biol Ther; 2005 Jun; 5(6):841-52. PubMed ID: 15952914
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin.
Moshitzky S; Kukulansky T; Haimovich J; Hollander N
Immunol Cell Biol; 2008; 86(3):261-7. PubMed ID: 18195726
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
Titzer S; Christensen O; Manzke O; Tesch H; Wolf J; Emmerich B; Carsten C; Diehl V; Bohlen H
Br J Haematol; 2000 Mar; 108(4):805-16. PubMed ID: 10792287
[TBL] [Abstract][Full Text] [Related]
10. Boosting anti-idiotype immune response with recombinant AAV enhances tumour protection induced by gene gun vaccination.
Cesco-Gaspere M; Zentilin L; Giacca M; Burrone OR
Scand J Immunol; 2008 Jul; 68(1):58-66. PubMed ID: 18482206
[TBL] [Abstract][Full Text] [Related]
11. Vaccine therapy for B-cell lymphomas: next-generation strategies.
Neelapu SS; Kwak LW
Hematology Am Soc Hematol Educ Program; 2007; ():243-9. PubMed ID: 18024636
[TBL] [Abstract][Full Text] [Related]
12. Vaccination strategies in the treatment of lymphomas.
Veelken H; Osterroth F
Oncology; 2002; 62(3):187-200. PubMed ID: 12065865
[TBL] [Abstract][Full Text] [Related]
13. Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.
Park HJ; Neelapu SS
Br J Haematol; 2008 Jun; 142(2):179-91. PubMed ID: 18422783
[TBL] [Abstract][Full Text] [Related]
14. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
[TBL] [Abstract][Full Text] [Related]
16. Idiotypic vaccination in B-cell malignancies.
Bianchi A; Massaia M
Mol Med Today; 1997 Oct; 3(10):435-41. PubMed ID: 9358470
[TBL] [Abstract][Full Text] [Related]
17. Current status of therapeutic vaccines for non-Hodgkin's lymphoma.
Hurvitz SA; Timmerman JM
Curr Opin Oncol; 2005 Sep; 17(5):432-40. PubMed ID: 16093791
[TBL] [Abstract][Full Text] [Related]
18. Anti-idiotypic DNA vaccines for B-cell lymphoma therapy.
Benvenuti F; Cesco-Gaspere M; Burrone OR
Front Biosci; 2002 Jan; 7():d228-34. PubMed ID: 11779689
[TBL] [Abstract][Full Text] [Related]
19. Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness.
Ashour AK; Petersen JL; McIlhaney MM; Vose JM; Solheim JC
Hybridoma (Larchmt); 2006 Oct; 25(5):306-8. PubMed ID: 17044787
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in multiple myeloma immunotherapy.
Ruffini PA; Biragyn A; Kwak LW
Biomed Pharmacother; 2002 May; 56(3):129-32. PubMed ID: 12046683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]